All Type of News
Influenza A benfits biotech firms
As H1N1 influenza claimed the lives of two Koreans over the weekend, shares of biotech companies surged on August 18, although the benchmark KOSPI headed down.
Green Cross Corp., the only Korean company with a faci...
Government to designate pharmacies to supply antiviral drugs
Amid a growing fear of the H1N1 flu pandemic in the upcoming cooler season, the government said it will designate pharmacies across the country to dispense antiviral drugs, including Tamiflu, which could treat patient...
Caspase inhibitor in Phase IIb clinical trial
LG Life Sciences, Ltd. (LGLS) says that its US partner Gilead Sciences is conducting a Phase IIb clinical trial in 240 patients chronically infected with the hepatitis C virus to evaluate caspase inhibitors, which was...
Daewoong’s generic isotretinoin fares well
Daewoong Pharm said its generic isotretinoin has received better recognition from the market due to newly modified PTP (press through pack) package.
The PTP package has contributed much to patients’ compliance and ...
Drugs blacklisted over harmful talc to be scrapped soon
1,122 drugs and medical goods confirmed to have used talc contaminated with asbestos will be discarded within this month, according to the Korea Food and Drug Administration.
The drug agency will also mete out some...
Influenza A kills 2 Koreans
Two Koreans died on August 15 and 16 from complications apparently caused by the flu virus, which has claimed the lives of almost 1,500 people across the world. One of the two was in his 50s and the other in her 60s.
...
Korea to vaccinate 13 million people
The Korean government plans to offer the vaccine to 13 million people, or 27 percent of the total population by mid-November. The figure was decided at a panel meeting of the Vaccination Review Board at the Health Min...
Advance payment of rebate is subject to price reduction
Health, Welfare Minister Jeon Jae-hee expressed her strong will to eradicate the pervasive rebate practices, saying the government will forcibly lower drug prices by up to 20 percent if drug makers are found to offer ...
Boryung to build W20 billion cGMP plant
Boryung Pharm said on August 14 it will invest 20 billion won to build a new cGMP plant producing the raw materials of fimasartan, a novel, non-peptide angiotensin II receptor antagonist and other finished products.
...
383 new and chemically modified drugs under development
A total of 383 research projects aiming at developing new and chemically modified medicines have been undertaken by 38 Korean companies, according to a white paper released by the Korea Drug Research Association on Au...
